RESUMEN
The interferon (IFN)-inducible double stranded (ds) RNA-activated protein kinase PKR plays an important role in protein synthesis by modulating the phosphorylation of the alpha-subunit of eukaryotic initiation fact 2 (eIF-2 alpha). In addition to translational control, PKR has been implicated in several signaling pathways leading to gene transcription. For example, PKR induces I kappa B alpha kinase (IKK) activity and I kappa B alpha phosphorylation leading to the induction of NF-kappa B-mediated gene transcription. Recent findings suggested that NF-kappa B activation by PKR does not require the catalytic activity of the kinase. Here, we provide novel evidence that induction of IKK and NF-kappa B activities proceeds independently of the dsRNA-binding properties of PKR and also verify the kinase-free role of PKR in this process. We also show that the effects of PKR mutants on IKK and NF-kappa B activation are independent of cell transformation but are dependent on the amount of the mutant PKR proteins expressed in cells. These data strongly support an indirect role of PKR in I kappa B alpha phosphorylation by modulating IKK activity through pathways that do not utilize the enzymatic and dsRNA-binding properties of PKR.
Asunto(s)
Interferones/farmacología , Proteínas Serina-Treonina Quinasas/metabolismo , ARN Bicatenario/metabolismo , eIF-2 Quinasa/fisiología , Células 3T3 , Animales , Catálisis , Transformación Celular Neoplásica , ADN/metabolismo , Activación Enzimática , Humanos , Quinasa I-kappa B , Ratones , Proteína Quinasa 8 Activada por Mitógenos , Proteínas Quinasas Activadas por Mitógenos/metabolismo , FN-kappa B/metabolismo , Fosforilación , Activación TranscripcionalRESUMEN
Epstein-Barr virus (EBV) latent infection is tightly associated with the development of lymphoid and epithelial human malignancies. The disruption of cell-growth checkpoints is mediated by a limited number of viral proteins that interfere with signal transduction mechanisms and transcription control in the infected cell. Genetic and biochemical evidence supports the notion that EBV-mediated transformation relies extensively on interference with cytokine signaling networks. This is achieved through direct modulation of cytokine receptor signaling mechanisms as well as alterations in the expression levels of various cytokines. The principal effector of these interventions is the EBV latent membrane protein 1 (LMP1) which plays a central role in the transformation process. This viral protein mimics activated receptors of the tumor necrosis factor receptor superfamily to promote cell growth and antiapoptotic mechanisms. LMP1 and other EBV latent proteins upregulate cytokines and growth factors which participate in autocrine and paracrine loops that are likely to promote cell transformation and modulate immune responses. This report will review the molecular mechanisms that underlie the disruption of cytokine signaling mechanisms in EBV-mediated transformation with a particular emphasis on the LMP1 mechanism of function.
Asunto(s)
Linfocitos B/patología , Linfocitos B/virología , Transformación Celular Neoplásica/patología , Citocinas/metabolismo , Herpesvirus Humano 4/fisiología , Transducción de Señal , Animales , Transformación Celular Neoplásica/metabolismo , Humanos , Modelos Biológicos , Proteínas de la Matriz Viral/química , Proteínas de la Matriz Viral/metabolismoRESUMEN
Homozygosity for the aly point mutation in NF-kappaB-inducing kinase (NIK) results in alymphoplasia in mice, a phenotype similar to that of homozygosity for deletion of the lymphotoxin beta receptor (LTbetaR). We now find that NF-kappaB activation by Epstein-Barr virus latent membrane protein 1 (LMP1) or by an LMP1 transmembrane domain chimera with the LTbetaR signaling domain in human embryonic kidney 293 cells is selectively inhibited by a wild type dominant negative NIK comprised of amino acids 624-947 (DN-NIK) and not by aly DN-NIK. In contrast, LMP1/CD40 is inhibited by both wild type (wt) and aly DN-NIK. LMP1, an LMP1 transmembrane domain chimera with the LTbetaR signaling domain, and LMP1/CD40 activate NF-kappaB in wt or aly murine embryo fibroblasts. Although wt and aly NIK do not differ in their in vitro binding to tumor necrosis factor receptor-associated factor 1, 2, 3, or 6 or in their in vivo association with tumor necrosis factor receptor-associated factor 2 and differ marginally in their very poor binding to IkappaB kinase beta (IKKbeta), only wt NIK is able to bind to IKKalpha. These data are compatible with a model in which activation of NF-kappaB by LMP1 and LTbetaR is mediated by an interaction of NIK or a NIK-like kinase with IKKalpha that is abrogated by the aly mutation. On the other hand, CD40 mediates NF-kappaB activation through a kinase that interacts with a different component of the IKK complex.
Asunto(s)
Mutación , FN-kappa B/metabolismo , Proteínas Serina-Treonina Quinasas/genética , Receptores del Factor de Necrosis Tumoral/metabolismo , Proteínas de la Matriz Viral/metabolismo , Secuencia de Bases , Antígenos CD40/metabolismo , Línea Celular , Cartilla de ADN , Humanos , Quinasa I-kappa B , Receptor beta de Linfotoxina , Mutagénesis Sitio-Dirigida , Proteínas Serina-Treonina Quinasas/metabolismo , Quinasa de Factor Nuclear kappa BRESUMEN
The X-linked lymphoproliferative syndrome (XLP) is a genetic disorder in which affected males have a morbid or fatal response to Epstein-Barr virus infection. The XLP deficiency has been mapped to a gene encoding a 128-residue protein, SH2D1A, which is comprised principally of a Src homology 2 (SH2) domain. We now report that SH2D1A associates with Dok1, a protein that interacts with Ras-GAP, Csk, and Nck. An SH2D1A SH2 domain mutant that has been identified in XLP does not associate with Dok1, in accord with the hypothesis that this interaction is linked to XLP. The association of SH2D1A with Dok1 also depends on phosphorylation of Dok1 Y(449) in the sequence ALYSQVQK. Further, overexpression of SH2D1A is found to activate NF-kappaB in 293T cells. NF-kappaB activation by SH2D1A does not depend on the wild-type SH2 domain and is inhibited by a dominant-negative IkappaB kinase beta. Thus, SH2D1A can affect multiple intracellular signaling pathways that are potentially important in the normal effective host response to Epstein-Barr virus infection.
Asunto(s)
Proteínas Portadoras/genética , Proteínas de Unión al ADN , Péptidos y Proteínas de Señalización Intracelular , Trastornos Linfoproliferativos/genética , FN-kappa B/genética , Fosfoproteínas/genética , Proteínas de Unión al ARN , Proteínas Portadoras/metabolismo , Infecciones por Virus de Epstein-Barr/genética , Regulación de la Expresión Génica , Predisposición Genética a la Enfermedad , Humanos , Trastornos Linfoproliferativos/metabolismo , Masculino , FN-kappa B/metabolismo , Fosfoproteínas/metabolismo , Proteína Asociada a la Molécula de Señalización de la Activación Linfocitaria , Síndrome , Células Tumorales Cultivadas , Cromosoma XRESUMEN
Epstein-Barr virus (EBV) transforms resting primary human B lymphocytes into indefinitely proliferating lymphoblastoid cell lines in vitro and is associated with several human malignancies in vivo. Recombinant EBV genetic analyses combined with in vitro B lymphocyte transformation assays demonstrate that latent infection membrane protein 1 (LMP1) is essential for EBV-mediated lymphocyte transformation. LMP1 has no intrinsic enzymatic activity but instead aggregates cellular proteins of the tumor necrosis factor receptor signaling pathway to activate transcription factor NF-kappaB. Mutants rendering LMP1 defective in these protein interactions are impaired in their abilities to activate NF-kappaB in reporter gene assays. Concordantly, EBV recombinants with LMP1 mutations that are compromised for NF-kappaB activation are impaired for growth transformation. Thus, EBV-mediated growth transformation is genetically and biochemically linked to LMP1-mediated activation of NF-kappaB.
Asunto(s)
Transformación Celular Viral , Herpesvirus Humano 4/genética , Proteínas I-kappa B , FN-kappa B/fisiología , Proteínas de la Matriz Viral/fisiología , Apoptosis , Linfocitos B/patología , Proteínas de Unión al ADN/fisiología , Humanos , Activación de Linfocitos , Inhibidor NF-kappaB alfa , Proteínas/fisiología , Receptores del Factor de Necrosis Tumoral/fisiología , Factor 1 Asociado a Receptor de TNFRESUMEN
In this study, we investigated the induction of cellular gene expression by the Epstein-Barr Virus (EBV) latent membrane protein 1 (LMP1). Previously, LMP1 was shown to induce the expression of ICAM-1, LFA-3, CD40, and EBI3 in EBV-negative Burkitt lymphoma (BL) cells and of the epidermal growth factor receptor (EGF-R) in epithelial cells. We now show that LMP1 expression also increased Fas and tumor necrosis factor receptor-associated factor 1 (TRAF1) in BL cells. LMP1 mediates NF-kappaB activation via two independent domains located in its C-terminal cytoplasmic tail, a TRAF-interacting site that associates with TRAF1, -2, -3, and -5 through a PXQXT/S core motif and a TRADD-interacting site. In EBV-transformed B cells or transiently transfected BL cells, significant amounts of TRAF1, -2, -3, and -5 are associated with LMP1. In epithelial cells, very little TRAF1 is expressed, and only TRAF2, -3, and -5, are significantly complexed with LMP1. The importance of TRAF binding to the PXQXT/S motif in LMP1-mediated gene induction was studied by using an LMP1 mutant that contains alanine point mutations in this motif and fails to associate with TRAFs. This mutant, LMP1(P204A/Q206A), induced 60% of wild-type LMP1 NF-kappaB activation and had approximately 60% of wild-type LMP1 effect on Fas, ICAM-1, CD40, and LFA-3 induction. In contrast, LMP1(P204A/Q206A) was substantially more impaired in TRAF1, EBI3, and EGF-R induction. Thus, TRAF binding to the PXQXT/S motif has a nonessential role in up-regulating Fas, ICAM-1, CD40, and LFA-3 expression and a critical role in up-regulating TRAF1, EBI3, and EGF-R expression. Further, D1 LMP1, an LMP1 mutant that does not aggregate failed to induce TRAF1, EBI3, Fas, ICAM-1, CD40, and LFA-3 expression confirming the essential role for aggregation in LMP1 signaling. Overexpression of a dominant form of IkappaBalpha blocked LMP1-mediated TRAF1, EBI3, Fas, ICAM-1, CD40, and LFA-3 up-regulation, indicating that NF-kappaB is an important component of LMP1-mediated gene induction from both the TRAF- and TRADD-interacting sites.
Asunto(s)
Regulación Viral de la Expresión Génica , Herpesvirus Humano 4/metabolismo , FN-kappa B/metabolismo , Receptores del Factor de Necrosis Tumoral/metabolismo , Proteínas de la Matriz Viral/metabolismo , Sitios de Unión , Línea Celular Transformada , Receptores ErbB/genética , Humanos , Molécula 1 de Adhesión Intercelular/genética , Unión Proteica , Activación Transcripcional , Regulación hacia ArribaRESUMEN
The Epstein-Barr virus oncoprotein latent infection membrane protein 1 (LMP1) is a constitutively aggregated pseudo-tumor necrosis factor receptor (TNFR) that activates transcription factor NF-kappaB through two sites in its C-terminal cytoplasmic domain. One site is similar to activated TNFRII in associating with TNFR-associated factors TRAF1 and TRAF2, and the second site is similar to TNFRI in associating with the TNFRI death domain interacting protein TRADD. TNFRI has been recently shown to activate NF-kappaB through association with TRADD, RIP, and TRAF2; activation of the NF-kappaB-inducing kinase (NIK); activation of the IkappaB alpha kinases (IKKalpha and IKKbeta); and phosphorylation of IkappaB alpha. IkappaB alpha phosphorylation on Ser-32 and Ser-36 is followed by its degradation and NF-kappaB activation. In this report, we show that NF-kappaB activation by LMP1 or by each of its effector sites is mediated by a pathway that includes NIK, IKKalpha, and IKKbeta. Dominant negative mutants of NIK, IKKalpha, or IKKbeta substantially inhibited NF-kappaB activation by LMP1 or by each of its effector sites.
Asunto(s)
Herpesvirus Humano 4/patogenicidad , FN-kappa B/metabolismo , Proteínas de la Matriz Viral/metabolismo , Animales , Sitios de Unión/genética , Línea Celular , Humanos , Quinasa I-kappa B , Técnicas In Vitro , Mutación , Fosforilación , Proteínas Serina-Treonina Quinasas/genética , Proteínas Serina-Treonina Quinasas/metabolismo , Conejos , Reticulocitos/metabolismo , Transducción de Señal , Transfección , Proteínas de la Matriz Viral/genética , Quinasa de Factor Nuclear kappa BRESUMEN
The EBV latent infection transforming protein, LMP1, has six hydrophobic transmembrane domains that enable it to aggregate in the plasma membrane and a 200-amino acid carboxyl-terminal cytoplasmic domain (CT) that activates nuclear factor-kappaB and induces many of the phenotypic changes in B lymphocytes that accompany CD40 activation. Since the phenotypic effects of LMP1 are similar to those of activated CD40, we now compare signaling from the LMP1 CT with that from the CD40 CT fused to the LMP1 transmembrane domains. The LMPCD40 chimera was similar to LMP1 in nuclear factor-kappaB activation and in up-regulation of epidermal growth factor receptor expression. CD40 ligation was known to activate the stress-activated protein kinase, and both LMPCD40 and LMP1 are now shown to induce stress-activated protein kinase activity in the absence of ligand. Deletion of the first four transmembrane domains of LMP1 abrogated LMP1 aggregation in the plasma membrane and nearly abolished signaling from LMP1 or the LMPCD40 chimera. These results highlight the role of LMP1 as a constitutively active receptor similar to CD40 and provide a novel approach for the generation of ligand-independent receptors.
Asunto(s)
Antígenos CD40/genética , Proteínas Quinasas Dependientes de Calcio-Calmodulina/metabolismo , Receptores ErbB/metabolismo , Proteínas de la Membrana/genética , Proteínas Quinasas Activadas por Mitógenos , FN-kappa B/metabolismo , Proteínas Recombinantes de Fusión/inmunología , Proteínas de la Matriz Viral/genética , Fusión Artificial Génica , Antígenos CD40/fisiología , Línea Celular , Activación Enzimática/genética , Activación Enzimática/inmunología , Herpesvirus Humano 4/genética , Herpesvirus Humano 4/inmunología , Humanos , Proteínas Quinasas JNK Activadas por Mitógenos , Proteínas de la Membrana/inmunología , Estructura Terciaria de Proteína , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/fisiología , Células Tumorales Cultivadas , Proteínas de la Matriz Viral/inmunologíaRESUMEN
The switch from latency to viral replication in Epstein-Barr virus (EBV)-transformed human B cells is mediated by Zta, the protein product of immediate-early EBV gene BZLF1. BZLF1 transcription is normally suppressed in EBV-transformed B cells but can be induced in some cell lines upon ligation of surface immunoglobulin by mechanisms that include the activation of Ca(2+)-dependent signaling pathways. The multifunctional Ca2+/calmodulin-dependent kinase type IV/Gr (CaMKIV/Gr) is normally absent in primary human B cells, but its expression is induced by the EBV oncoprotein LMP1 in the course of B-cell growth transformation by EBV. In this study, we demonstrate that activated CaMKIV/Gr induces transcription from the BZLF1 promoter and upregulates the expression of Zta in permissive cells. Transcriptional activation of the BZLF1 promoter by CaMKIV/Gr is dependent on the CREB/AP1 binding element ZII and is greatly augmented by the Ca2+/calmodulin-dependent phosphatase calcineurin. These results outline a virus-regulated mechanism involving CaMKIV/Gr which promotes transition from latency to productive viral replication in response to Ca(2+)-mobilizing extracellular signals.
Asunto(s)
Proteínas Quinasas Dependientes de Calcio-Calmodulina/metabolismo , Calcio/metabolismo , Proteínas de Unión al ADN/genética , Herpesvirus Humano 4/fisiología , Transactivadores/genética , Proteínas Virales/genética , Activación Viral , Sitios de Unión , Proteína Quinasa Tipo 4 Dependiente de Calcio Calmodulina , Proteína de Unión a Elemento de Respuesta al AMP Cíclico/metabolismo , Proteínas de Unión al ADN/fisiología , Humanos , Regiones Promotoras Genéticas , Transactivadores/fisiología , Factor de Transcripción AP-1/metabolismo , Transcripción Genética , Células Tumorales Cultivadas , Regulación hacia Arriba , Proteínas Virales/fisiología , Latencia del Virus , Replicación ViralRESUMEN
Rel/NF-kappa B is a ubiquitous transcription factor that consists of multiple polypeptide subunits, and is subject to complex regulatory mechanisms that involve protein-protein interactions, phosphorylation, ubiquitination, proteolytic degradation, and nucleocytoplasmic translocation. The sophisticated control of Rel/NF-kappa B activity is not surprising since this transcription factor is involved in a wide array of cellular responses to extracellular cues, associated with growth, development, apoptosis, and pathogen invasion. Thus, it is not unexpected that this versatile cellular homeostatic switch would be affected by a variety of viral pathogens, which have evolved mechanisms to utilize various aspects of Rel/NF-kappa B activity to facilitate their replication, cell survival and possibly evasion of immune responses. This review will cover the molecular mechanisms that are utilized by mammalian oncogenic viruses to affect the activity of Rel/NF-kappa B transcription factors and the role of Rel/NF-kappa B in the regulation of viral gene expression and replication.
Asunto(s)
Transformación Celular Viral/genética , Regulación Viral de la Expresión Génica/genética , FN-kappa B/fisiología , Proteínas Proto-Oncogénicas/fisiología , Factores de Transcripción , Animales , Linfocitos B , Proteínas de Unión al ADN , Productos del Gen tax , Virus de la Hepatitis B/genética , Herpesvirus Humano 4/genética , Virus Linfotrópico T Tipo 1 Humano/genética , Humanos , Proteínas Oncogénicas Virales , Proteínas , Transducción de Señal , Factor 3 Asociado a Receptor de TNF , Transactivadores , Factor de Transcripción ReIB , Proteínas de la Matriz Viral , Proteínas Reguladoras y Accesorias Virales , Replicación ViralRESUMEN
The binding of heterotrimeric lymphotoxin, LT alpha1 beta2, to the LTbeta receptor (LTbeta R), a member of the tumor necrosis factor receptor (TNFR) superfamily, induces nuclear factor kappaB (NF-kappaB) activation and cell death in HT29 adenocarcinoma cells. We now show that treatment with LT alpha1 beta2 or agonistic LTbeta R antibodies causes rapid recruitment of TNFR-associated factor 3 (TRAF3) to the LTbeta R cytoplasmic domain. Further, stable overexpression of a TRAF3 mutant that lacks the RING and zinc finger domains inhibits LTbeta R-mediated cell death. The inhibition is specific for LTbeta R cell death signaling, since NF-kappaB activation by LT alpha1 beta2 and Fas-mediated apoptosis are not inhibited in the same cells. The mutant and endogenous TRAF3s are both recruited at equimolar amounts to the LTbeta R, suggesting that the mutant disrupts the function of the signaling complex. These results implicate TRAF3 as a critical component of the LTbeta R death signaling complex and indicate that at least two independent signaling pathways are initiated by LTbeta R ligation.
Asunto(s)
Muerte Celular , Linfotoxina-alfa/farmacología , FN-kappa B/metabolismo , Proteínas/fisiología , Receptores del Factor de Necrosis Tumoral/fisiología , Factor de Necrosis Tumoral alfa/farmacología , Adenocarcinoma , Anticuerpos/farmacología , Secuencia de Bases , Muerte Celular/efectos de los fármacos , Línea Celular , Cartilla de ADN , Humanos , Receptor beta de Linfotoxina , Datos de Secuencia Molecular , Mutagénesis Sitio-Dirigida , Reacción en Cadena de la Polimerasa , Biosíntesis de Proteínas , Multimerización de Proteína , Receptores del Factor de Necrosis Tumoral/inmunología , Proteínas Recombinantes/metabolismo , Eliminación de Secuencia , Transducción de Señal , Factor 3 Asociado a Receptor de TNF , Transfección , Dedos de Zinc , Receptor fas/inmunología , Receptor fas/fisiologíaRESUMEN
Immunohistochemical localization of human fascin, a distinct 55-kd actin-bundling protein, was determined for a wide variety of lymphoid tissues (364 specimens total). In non-neoplastic tissues, reactivity was highly selective and localized predominantly in dendritic cells. In the thymus, this protein was distinctly localized to medullary dendritic cells. In reactive nodes, interdigitating reticulum cells of T zones, cells in subcapsular areas, and cells of the reticular network were reactive, with variable reactivity observed for follicular dendritic cells. Splenic dendritic cells of the white pulp and sinus-lining cells of the red pulp were reactive. Endothelial cells of all tissues exhibited variable reactivity. Lymphoid cells, myeloid cells, and plasma cells were uniformly nonreactive. In the peripheral blood, only dendritic (veiled) cells were reactive for fascin. A striking finding was observed for cases of Hodgkin's disease (total 187 cases). In all cases of nodular sclerosis (132), mixed cellularity (34), lymphocyte depletion (2), and unclassified types (5), all or nearly all Reed-Sternberg cells and variants were immunoreactive for fascin. Neoplastic cells exhibited strong diffuse cytoplasmic staining and frequently assumed dendritic shapes, particularly in the nodular sclerosis type, producing an interdigitating meshwork or syncytial network of cells. In cases of mixed cellularity type, neoplastic cells generally appeared more discrete. In all 14 cases of nodular lymphocyte predominance type, L&H variants were nonreactive. By contrast, neoplastic lymphoid cells of only 24 of 156 (15%) other lymphoid neoplasms (127 B cell, 27 T cell, and two null cell evaluated) were reactive for fascin. Fascin represents a highly effective marker for detection of certain dendritic cells in normal and neoplastic tissues, is an extremely consistent marker for Reed-Sternberg cells and variants of Hodgkin's disease (except L&H types), and may be helpful to distinguish between Hodgkin's disease and non-Hodgkin's lymphoma in difficult cases. The staining profile for fascin raises the possibility of a dendritic cell derivation, particularly an interdigitating reticulum cell, for the neoplastic cells of Hodgkin's disease, notably in nodular sclerosis type. However, as fascin expression may be induced by Epstein-Barr virus infection of B cells, the possibility that viral induction of fascin in lymphoid or other cell types must also be considered in Epstein-Barr virus-positive cases.
Asunto(s)
Proteínas Portadoras/metabolismo , Enfermedad de Hodgkin/metabolismo , Enfermedad de Hodgkin/patología , Proteínas de Microfilamentos , Células de Reed-Sternberg/metabolismo , Linfocitos B/citología , Biomarcadores , Línea Celular , Células Dendríticas/citología , Humanos , Inmunohistoquímica , Tejido Linfoide/citología , Tejido Linfoide/metabolismo , Tejido Linfoide/patología , Linfoma no Hodgkin/metabolismo , Linfoma no Hodgkin/patología , Células de Reed-Sternberg/patología , Valores de ReferenciaRESUMEN
The Epstein-Barr virus (EBV)-encoded LMP1 protein induces several cellular changes including induction of epidermal growth factor receptor (EGFR) expression and activation of the NF-kappaB transcription factor. Two domains within the carboxy terminus have been identified that activate NF-kappaB. In this study, mutational analysis of the LMP1 protein indicated that the proximal NF-kappaB activation domain, which is identical to the TRAF interaction domain (amino acids 187 to 231), is essential for induction of the EGFR. The distal NF-kappaB activation domain (amino acids 352 to 386) did not induce expression of the EGFR. In contrast, the two domains both independently activated a kappaB-CAT reporter gene and induced expression of the NF-kappaB-regulated A20 gene in C33A epithelial cells. These results indicate that induction of the EGFR by LMP1 involves the TRAF interaction domain and that activation of NF-kappaB alone is not sufficient. Northern blot analysis revealed that induction of EGFR and A20 expression is likely to be at the transcriptional level. Interestingly expression of CD40 in the C33A cells also induced expression of the EGFR. Overexpression of either TRAF3 or an amino-terminal-truncated form of TRAF3 (TRAF3-C) inhibited signaling from the LMP1 TRAF interaction domain but did not affect signaling from the distal NF-kappaB activation domain. These data further define the mechanism by which LMP1 induces expression of the EGFR and indicate that TRAF signaling from LMP1 and CD40 activates a downstream transcription pathway distinct from NF-kappaB that induces expression of the EGFR.
Asunto(s)
Receptores ErbB/metabolismo , Herpesvirus Humano 4/metabolismo , FN-kappa B/metabolismo , Proteínas/metabolismo , Transducción de Señal/fisiología , Proteínas de la Matriz Viral/metabolismo , Animales , Sitios de Unión , Antígenos CD40/metabolismo , Cisteína Endopeptidasas , Proteínas de Unión al ADN , Receptores ErbB/genética , Expresión Génica , Humanos , Péptidos y Proteínas de Señalización Intracelular , Ratones , Mutagénesis , FN-kappa B/genética , Proteínas Nucleares , Proteínas/genética , ARN Mensajero , Factor 3 Asociado a Receptor de TNF , Células Tumorales Cultivadas , Proteína 3 Inducida por el Factor de Necrosis Tumoral alfa , Factor de Necrosis Tumoral alfa/metabolismo , Proteínas de la Matriz Viral/genéticaRESUMEN
The Epstein-Barr virus (EBV) transforming protein LMP1 appears to be a constitutively activated tumor necrosis factor receptor (TNFR) on the basis of an intrinsic ability to aggregate in the plasma membrane and an association of its cytoplasmic carboxyl terminus (CT) with TNFR-associated factors (TRAFs). We now show that in EBV-transformed B lymphocytes most of TRAF1 or TRAF3 and 5% of TRAF2 are associated with LMP1 and that most of LMP1 is associated with TRAF1 or TRAF3. TRAF1, TRAF2, and TRAF3 bind to a single site in the LMP1 CT corresponding to amino acids (aa) 199 to 214, within a domain which is important for B-lymphocyte growth transformation (aa 187 to 231). Further deletional and alanine mutagenesis analyses and comparison with TRAF binding sequences in CD40, in CD30, and in the LMP1 of other lymphycryptoviruses provide the first evidence that PXQXT/S is a core TRAF binding motif. The negative effects of point mutations in the LMP1(1-231) core TRAF binding motif on TRAF binding and NF-kappaB activation genetically link the TRAFs to LMP1(1-231)-mediated NF-kappaB activation. NF-kappaB activation by LMP1(1-231) is likely to be mediated by TRAF1/TRAF2 heteroaggregates since TRAF1 is unique among the TRAFs in coactivating NF-kappaB with LMP1(1-231), a TRAF2 dominant-negative mutant can block LMP1(1-231)-mediated NF-kappaB activation as well as TRAF1 coactivation, and 30% of TRAF2 is associated with TRAF1 in EBV-transformed B cells. TRAF3 is a negative modulator of LMP1(1-231)-mediated NF-kappaB activation. Surprisingly, TRAF1, -2, or -3 does not interact with the terminal LMP1 CT aa 333 to 386 which can independently mediate NF-kappaB activation. The constitutive association of TRAFs with LMP1 through the aa 187 to 231 domain which is important in NF-kappaB activation and primary B-lymphocyte growth transformation implicates TRAF aggregation in LMP1 signaling.
Asunto(s)
Herpesvirus Humano 4 , Proteínas/genética , Proteínas de la Matriz Viral/genética , Linfocitos B/metabolismo , Linfocitos B/virología , Transformación Celular Viral/genética , Regulación de la Expresión Génica , Humanos , FN-kappa B/genética , Proteínas/metabolismo , Factor 1 Asociado a Receptor de TNF , Factor 2 Asociado a Receptor de TNF , Factor 3 Asociado a Receptor de TNF , Células Tumorales Cultivadas , Proteínas de la Matriz Viral/metabolismoRESUMEN
CD40 signalings play crucial roles in B-cell function. To identify molecules which transduce CD40 signalings, we have utilized the yeast two-hybrid system to clone cDNAs encoding proteins that bind the cytoplasmic tail of CD40. A cDNA encoding a putative signal transducer, designated TRAF6, has been molecularly cloned. TRAF6 has a tumor necrosis factor receptor (TNFR)-associated factor (TRAF) domain in its carboxyl terminus and has a RING finger domain, a cluster of zinc fingers and a coiled-coil domain, which are also present in other TRAF family proteins. TRAF6 does not associate with the cytoplasmic tails of TNFR2, CD30, lymphotoxin-beta receptor, and LMP1 of Epstein-Barr virus. Deletion analysis showed that residues 246-269 of CD40 which are required for its association with TRAF2, TRAF3, and TRAF5 are dispensable for its interaction with TRAF6, whereas residues 230-245 were required. Overexpression of TRAF6 activates transcription factor NFkappaB, and its TRAF-C domain suppresses NFkappaB activation triggered by CD40 lacking residues 246-277. These results suggest that TRAF6 could mediate the CD40 signal that is transduced by the amino-terminal domain (230-245) of the CD40 cytoplasmic region and appears to be independent of other known TRAF family proteins.
Asunto(s)
Antígenos CD40/metabolismo , Proteínas Portadoras/metabolismo , Proteínas , Transducción de Señal , Secuencia de Aminoácidos , Animales , Proteínas Portadoras/química , ADN Complementario , Humanos , Células Jurkat , Ratones , Ratones Endogámicos C57BL , Datos de Secuencia Molecular , FN-kappa B/metabolismo , Unión Proteica , Factor 6 Asociado a Receptor de TNF , Células Tumorales CultivadasRESUMEN
CD40, a member of the tumour necrosis factor receptor family, is expressed on the surface of B lymphocytes where its ligation provides a potent survival signal. CD40 is also expressed in basal epithelial cells and in a number of different carcinomas where its function remains unknown. We observed that contrary to the studies in normal B cells, CD40 ligation in carcinoma cell lines and in normal primary epithelial cells resulted in growth inhibition and enhanced susceptibility to apoptosis induced by anti-neoplastic drugs, TNF-alpha, Fas and ceramide. This effect was also observed in CD40-transfected Rat-1 fibroblasts. The expression of Bcl-2 did not affect growth inhibition induced by CD40 ligation in epithelial cells but the Epstein - Barr Virus-encoded latent membrane protein 1 (LMP1) blocked the effect. Whilst transient expression of LMP-1 resulted in the inhibition of epithelial cell growth, this effect was not observed with a LMP1 mutant lacking the binding domain for TRAF3, a protein which may mediate signal transduction by interacting with the cytoplasmic domains of both CD40 and LMP1. Transient expression of TRAF3 also inhibited epithelial cell growth, whilst expression of a dominant-negative TRAF3 partially blocked the inhibitory effect of CD40 ligation and of transient LMP1 expression. These results suggest that CD40 regulates epithelial cell growth in a manner mimicked by LMP1 and implicate TRAF3 as a common mediator in the transduction of the growth inhibitory signals generated via the CD40 and LMP1 pathways.
Asunto(s)
Apoptosis/efectos de los fármacos , Antígenos CD40/farmacología , Proteínas de la Matriz Viral/metabolismo , Animales , Antígenos CD40/genética , Antígenos CD40/metabolismo , División Celular/efectos de los fármacos , Supervivencia Celular/fisiología , Sinergismo Farmacológico , Células Epiteliales , Humanos , Proteínas/metabolismo , Ratas , Receptores del Factor de Necrosis Tumoral , Células Tumorales Cultivadas/metabolismo , Neoplasias de la Vejiga Urinaria/metabolismo , Neoplasias de la Vejiga Urinaria/patologíaRESUMEN
CD30 is a member of the tumor necrosis factor receptor superfamily, which can transduce signals for proliferation, death, or nuclear factor kappa B (NF-kappa B) activation. Investigation of CD30 signaling pathways using a yeast two-hybrid interaction system trapped a cDNA encoding the tumor necrosis factor receptor-associated factor (TRAF)-2 TRAF homology domain. TRAF-1 and TRAF-3 also interacted with CD30, and > 90% of in vitro-translated TRAF-1 or -2, or 50% of TRAF-3, bound to the CD30 cytoplasmic domain. TRAF-1, -2, and -3 bound mostly, but not exclusively, to the carboxyl-terminal 36 residues of CD30. The binding was strongly inhibited by a CD30 oligopeptide centered around a PXQXT (where X is any amino acid) motif shared with CD40 and the Epstein-Barr virus transforming protein LMP1, indicating that this motif in CD30 is an important determinant of TRAF-1, -2 or -3 interaction. At least 15% of TRAF-1, -2, or -3 associated with CD30 when coexpressed in 293 cells. The association was not affected by CD30 cross-linking. However, cross-linking of CD30 activated NF-kappa B. NF-kappa B activation was dependent on the carboxyl-terminal 36 amino acids of CD30 that mediate TRAF association. TRAF-2 has been previously shown to have a unique role in TRAF-mediated NF-kappa B activation, and NF-kappa B activation following CD30 cross-linking was blocked by a dominant negative TRAF-2 mutant. These data indicate that CD30 cross-linking-induced NF-kappa B activation is predominantly TRAF-2-mediated.
Asunto(s)
Antígeno Ki-1/metabolismo , FN-kappa B/metabolismo , Proteínas/metabolismo , Secuencia de Aminoácidos , Línea Celular , Citoplasma/metabolismo , Humanos , Antígeno Ki-1/biosíntesis , Antígeno Ki-1/química , Cinética , Datos de Secuencia Molecular , Reacción en Cadena de la Polimerasa , Biosíntesis de Proteínas , Proteínas/química , Proteínas Recombinantes de Fusión/metabolismo , Proteínas Recombinantes/metabolismo , Homología de Secuencia de Aminoácido , Factor 1 Asociado a Receptor de TNF , Factor 2 Asociado a Receptor de TNF , Factor 3 Asociado a Receptor de TNF , Activación Transcripcional , TransfecciónRESUMEN
Latent infection membrane protein 1 (LMP1), the Epstein-Barr virus transforming protein, associates with tumor necrosis factor receptor (TNFR) associated factor 1 (TRAF1) and TRAF3. Since TRAF2 has been implicated in TNFR-mediated NF-kappa B activation, we have evaluated the role of TRAF2 in LMP1-mediated NF-kappa B activation. TRAF2 binds in vitro to the LMP1 carboxyl-terminal cytoplasmic domain (CT), coprecipitates with LMP1 in B lymphoblasts, and relocalizes to LMP1 plasma membrane patches. A dominant negative TRAF2 deletion mutant that lacks amino acids 6-86 (TRAF/ delta 6-86) inhibits NF-kappa B activation from the LMP1 CT and competes with TRAF2 for LMP1 binding. TRAF2 delta 6-86 inhibits NF-kappa B activation mediated by the first 45 amino acids of the LMP1 CT by more than 75% but inhibits NF-kappa B activation through the last 55 amino acids of the CT by less than 40%. A TRAF interacting protein, TANK, inhibits NF-kappa B activation by more than 70% from both LMP1 CT domains. These data implicate TRAF2 aggregation in NF-kappa B activation by the first 45 amino acids of the LMP1 CT and suggest that a different TRAF-related pathway may be involved in NF-kappa B activation by the last 55 amino acids of the LMP1 CT.
Asunto(s)
Proteínas Adaptadoras Transductoras de Señales , Linfocitos B/metabolismo , Transformación Celular Viral , Regulación Viral de la Expresión Génica , Herpesvirus Humano 4/genética , FN-kappa B/fisiología , Proteínas/metabolismo , Proteínas/fisiología , Proteínas de la Matriz Viral/fisiología , Animales , Secuencia de Bases , Unión Competitiva , Humanos , Ratones , Datos de Secuencia Molecular , Unión Proteica , Factor 2 Asociado a Receptor de TNFRESUMEN
This study was initiated to examine the differential expression of an evolutionary conserved human 55-kd actin-bundling (p55) protein that is induced in B lymphocytes by Epstein-Barr virus infection. Our study demonstrates that p55 is specifically expressed at constitutively high levels in human peripheral blood dendritic cells and lymph node (interdigitating) dendritic cells. Blood dendritic cells constitute a minority (< 2%) of all blood leukocytes but are a distinct population of potent antigen-presenting cells. Immunofluorescence microscopy with a monoclonal antibody specific for p55 showed that 87% of peripheral blood dendritic cells stained brightly in the cytoplasm and in the veiled cytoplasmic extensions. In contrast, monocytes, granulocytes, T cells, and B lymphocytes showed no expression of the p55 protein. Western blot analysis confirmed that only the dendritic cell component of peripheral blood expressed high levels of p55. Staining of human lymph node sections demonstrated selective expression of the p55 antigen by dendritic cells in the T-cell-dependent areas but not in the B cell follicles. p55 is likely to be involved in the organization of a specialized microfilament cytoskeleton in the dendritic cells, and the anti-p55 antibody should be useful for further characterization of this important population of antigen-presenting cells in clinical transplantation, HIV-1 pathogenesis, and autoimmune diseases.
Asunto(s)
Proteínas Portadoras/biosíntesis , Células Dendríticas/metabolismo , Proteínas de Microfilamentos/biosíntesis , Actinas/metabolismo , Linfocitos B/química , Western Blotting , Proteínas Portadoras/análisis , Separación Celular , Células Cultivadas , Células Dendríticas/fisiología , Fluoresceína-5-Isotiocianato , Granulocitos/química , Humanos , Ganglios Linfáticos/química , Ganglios Linfáticos/citología , Prueba de Cultivo Mixto de Linfocitos , Proteínas de Microfilamentos/análisis , Monocitos/química , Linfocitos T/químicaRESUMEN
Epstein-Barr virus nuclear antigen 2 (EBNA 2) activates transcription of specific genes and is essential for B-lymphocyte transformation. EBNA 2 has an acidic activation domain which interacts with general transcription factors TFIIB, TFIIH, and TAF40. We now show that EBNA 2 is specifically bound to a novel nuclear protein, p100, and that p100 can coactivate gene expression mediated by the EBNA 2 acidic domain. The EBNA 2 acidic domain was used to affinity purify p100. cDNA clones encoding the p100 open reading frame were identified on the basis of peptide sequences of the purified protein. Antibody against p100 coimmunoprecipitated p100 and EBNA 2 from Epstein-Barr virus-transformed lymphocyte extracts, indicating that EBNA 2 and p100 are complexed in vivo. p100 overexpression in cells specifically augmented EBNA 2 acidic domain-mediated activation. The coactivating effect is probably mediated by p100 interaction with TFIIE. Bacterially expressed p100 specifically adsorbs TFIIE from nuclear extracts, and in vitro-translated p56 or p34 TFIIE subunit can independently bind to p100. p100 also appears to be essential for normal cell growth, since cell viability was reduced by antisense p100 RNA and restored by sense p100 RNA expression.